Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer

Fig. 2

Efficacy evaluation of rmhTNF combined with cisplatin versus cisplatin alone through thoracic perfusion for treating MPE. a Thoracic perfusion of rmhTNF combined with cisplatin has a higher ORR compared with cisplatin alone. b Thoracic perfusion of rmhTNF combined with cisplatin has a lower ORR compared with cisplatin alone. c Thoracic perfusion of rmhTNF combined with cisplatin improves the QOL of patients with MPE compared with cisplatin alone. ORR, overall response rate; NRR, non-response rate; OR, odds ratio; QOL, quality of life; rmhTNF, recombinant mutant human tumor necrosis factor injection; MPE, malignant pleural effusion

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us